News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck KGaA (MKGAF.PK) Terminates Multiple Schlerosis Drug License Agreement With Ono Pharmaceutical Company, Ltd.



6/17/2014 7:12:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - German drugmaker Merck KGaA agreed with Japan's Ono Pharmaceutical to terminate a license agreement over Ono's experimental multiple sclerosis (MS) drug ceralifimod.

Merck, the maker of MS drug Rebif, said on Tuesday the project did "not meet Merck's threshold for continued investment".

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at RTT News
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES